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Fighting infections
Mankin� is at risk �f l�sin� the fi�ht a�ainst infecti�us �isease,� as the 
success �f antibi�tics fa�es an� �e’re still ill-�re�are� f�r ne� viral 
�an�emics. Michael Gross re��rts. Fighting disease: In the first �eca�es after 
the intr��ucti�n �f antibi�tics,� there �as 
�i�es�rea� ��timism that the fi�ht a�ainst 
infecti�us �isease c�ul� be ��n. This early 
a�vert f�r �enicillin �as tar�ete� at W�rl� 
War II servicemen. (Picture: Wiki�e�ia.)F�r a fe� �eca�es,� ar�un� the 
mi��le �f the 20th century,� there �as 
�i�es�rea� ��timism that science 
c�ul� �in the fi�ht a�ainst infecti�us 
�iseases,� re�uce their s�rea� an� 
the �ama�e they �� t� the infecte�,� 
an� even era�icate s�me. Penicillin 
became available in the 1940s an�,� 
in the �eca�es after that,� m�re an� 
m�re antibi�tics �ere �evel��e� 
an� successfully use� in the fi�ht 
a�ainst �isease. On a se�arate 
fr�nt,� the successful era�icati�n 
�f small��x thr�u�h vaccinati�n 
sh��e� that �isease threats can be 
eliminate�. H��ever,� by the en� �f 
the 20th century,� small��x remaine� 
the �nly exam�le �f era�icati�n,� ne� 
�ath��ens emer�e�,� an� many �l� 
f�es,� such as tubercul�sis,� sa� a 
resur�ence.
Furtherm�re,� scientists f�un� 
that bacterial �ath��ens �evel�� 
resistance a�ainst existin� 
antibi�tics as fast as the �harma 
in�ustry can �evel�� ne� �nes. 
This threat �i�n’t arise entirely fr�m 
natural causes. It became clear in the 
1990s that the �i�es�rea� misuse 
an� �veruse �f antibi�tics,� such 
as their blanket use in a�riculture,� 
create� the envir�nments �here 
micr�bial strains are enc�ura�e� t� 
�ass ar�un� existin� resistance traits 
an� even t� �evel�� ne� �nes. 
F�r a �hile,� the in�ustry trie� t� 
kee� u� the race an� �evel��e� ne� 
antibi�tics,� but in recent years,� the 
�i�eline �rie� u�. As Laura Pi���ck 
fr�m the Antimicr�bial A�ents 
Research Gr�u� at the University 
�f Birmin�ham ��inte� �ut in a 
c�mment f�r The Lancet last year,� n� 
m�re than three antibacterial a�ents 
�ere a��r�ve� since 2008,� c�m�are� 
�ith 16 in the years 1983 t� 1987. 
Pi���ck lists several reas�ns f�r 
this �ecline in �ru� �evel��ment: 
“mer�ers bet�een �harmaceutical 
c�m�anies have re�uce� the number 
an� �iversity �f �ru�-�isc�very 
teams,� an� many c�m�anies have 
�ith�ra�n fr�m �evel��ment �f 
antibacterial �ru�s” she �rites. She als� ��ints �ut that initial h��es 
f�r �en�mics t� yiel� ne� tar�ets 
f�r antibacterial �ru�s have been 
�isa���inte�. Finally,� she ��ints 
�ut that f�r c�m�anies �evel��in� 
antibi�tics “the return �n investment 
is l�� because antibi�tics,� unlike 
many �ru�s,� are usually use� f�r 
sh�rt-term c�urses �f treatment 
(5–7 �ays).” T� im�r�ve the ec�n�mic 
viability �f such �ru�s she su��ests 
they mi�ht be s�l� at hi�her �rices,� 
es�ecially c�nsi�erin� the years �f 
life they save in c�m�aris�n t� m�re 
ex�ensive but less efficient cancer 
�ru�s. Alternatively,� ��vernments 
an� aca�emic instituti�ns c�ul� 
take u� m�re �f the research an� 
�evel��ment ��rk. 
“This is the �ara��x �e fin� 
�urselves in,�” says Pi���ck,� “at the 
very time �e have the kn��le��e t� 
�esi�n ne� an� effective antibi�tics,� 
fe� �harmaceutical c�m�anies �ish 
t� �evel�� them. In all likelih���,� 
�isc�very an� early research �ill be 
by aca�emic researchers an� clinical 
research an� �evel��ment by the 
c�mmercial sect�r. T� �et this m��el 
��rkin� effectively t� meet the 
bacterial infecti�n challen�es,� a ne� 
fun�in� m��el is require�.” 
What �as �nce the sin�le bi��est 
bacterial threat in in�ustrialise� 
c�untries,� the methicillin-resistant 
strains �f Staphylococcus aureus 
(MRSA),� seems t� have subsi�e� 
s�me�hat in the last fe� years. In 
2011,� the number �f rec�r�e� cases 
�f MRSA infecti�ns fell t� a rec�r� 
l��. This si�nificant success is the 
result �f the attenti�n hea�e� �n 
MRSA an� similar Gram-��sitive 
bacteria �n all levels fr�m �ru� 
�evel��ment thr�u�h t� clinical 
�ractice. But in the meantime,� 
Pi���ck �ia�n�ses,� there is a 
“�enuine rarity �f a�ents t� treat 
infecti�ns cause� by Gram-ne�ative 
bacteria.” 
Gram-ne�ative bacteria inclu�e 
E. coli an� the �neum�nia �ath��en 
Klebsiella pneumoniae. Resistance 
traits kn��n as NDM-1 an� KPC,� res�ectively,� make these bacteria 
resistant t� carba�enem antibi�tics 
an� c�ul� bec�me a threat in 
the future. As the �utbreak �f a 
�ath��enic E. coli strain in Germany 
in June 2011 has �em�nstrate� �nce 
m�re,� �an�er�us infecti�ns can 
c�me a��arently �ut �f n��here an� 
�reak hav�c even bef�re the me�ical 
ex�erts are able t� ��rk �ut �hat is 
��in� �n. 
The British S�ciety f�r 
Antimicr�bial Chem�thera�y has 
recently launche� a �l�bal initiative 
calle� Antibi�tic Acti�n (htt�://
antibi�tic-acti�n.c�m/),� �hich aims 
at “Inf�rmin� all ab�ut the nee� 
f�r �isc�very,� �evel��ment an� 
a��r��riate use �f antibi�tic a�ents.”
Alternatives to antibiotics
With hin�si�ht,� �ne mi�ht ar�ue that 
antibi�tics,� �ri�inally �evel��e� by 
fun�i,� �ere never ��in� t� �i�e �ut 
bacterial threats. After all,� bacteria 
have c�existe� �ith antibi�tic-
�r��ucin� fun�i f�r hun�re�s �f 
milli�ns �f years an� survive� 
by �evel��in� suitable �efence 
mechanisms. An� �ith a �enerati�n 
s�an that may be as sh�rt as 30 
minutes,� bacteria can ev�lve very 
quickly. In an attem�t t� by�ass 
the arms race bet�een antibi�tics 
�r��ucers an� their micr�bial 
tar�ets,� researchers are n�� 
c�nsi�erin� fun�amentally �ifferent 
s�luti�ns. 
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Achilles heel: Bacterial �ath��ens �ften   
 �e�en� �n �ili f�r their attachment t� h�st 
 tissues. Researchers are l��kin� f�r ne� 
�ru� can�i�ates that can interfere �ith the 
 c�m�lex self-assembly �f these �r�tein fibres 
at a s�ecialise� ��re c�m�lex (usher) in the 
�uter membrane (OM). Cha�er�nes in the 
�eri�lasm (P) �r�tect the in�ivi�ual buil�in� 
bl�cks fr�m a��re�ati�n. (A�a�te� fr�m 
Remaut et al. (2008),� Cell  133,� 640–652.)
Fire bird: In��nesian s�l�iers in �r�tective cl�sin� thr�� a slau�htere� chicken int� fire �urin� 
a j�int bir� flu �reventi�n �rill carrie� �ut in Jakarta,� In��nesia,� in 2008. In��nesia has rec�r�e� 
m�re than 100 human �eaths fr�m bir� flu since 2003. (Ph�t�: AP Ph�t�/Ir�in Fe�riansyah.)Firstly,� alth�u�h �en�mics has 
faile� t� �r�vi�e ne� miracle cures 
f�r infecti�us �iseases,� it may still 
save the �ay in c�mbinati�n �ith 
existin� �ru�s. If an� �hen �en�mic 
analysis at the ��int �f care bec�mes 
a r�utine �r�ce�ure,� ��ct�rs c�ul� 
establish the �recise nature �f a 
bacterial infecti�n inclu�in� the 
�resence �f any resistance traits. 
This ��ul� all�� them t� a��ly 
existin� �ru�s much m�re selectively 
an� efficiently. It ��ul� als� im�r�ve 
the c�st efficiency �f clinical trials 
f�r ne� antimicr�bial a�ents,� 
as �ne c�ul� select trial �r�u�s 
�ith infecti�ns fr�m a s�ecific,� 
�ell-�efine� �ath��en. 
It may als� be a ���� i�ea t� a��ly
�ru�s that ��n’t kill bacteria but �nly 
su��ress �ath��enic traits such 
as t�xin secreti�n �r c�l�nisati�n 
�f their h�st. The fun�amental 
�ifference is that a �ru� that st��s,� 
f�r instance,� E. coli fr�m attachin� 
t� the human urinary tract �ith�ut killin� the bacteria ��esn’t exert as 
much �f a selective �ressure as an 
antibi�tic that ��ses an a�a�t-�r-�ie 
threat t� the micr�bes,� an� theref�re 
��ul�n’t carry nearly as bi� a risk �f 
resistance �r�blems. Furtherm�re,� 
a��r�aches that �nly �isarm the 
�ath��en are less likely t� affect the 
‘frien�ly’ bacteria in �ur intestines,� 
ex�erts believe.
One �r�misin� tar�et �f such 
alternative antimicr�bials is the 
assembly �f the �ili,� the ‘hairs’ that 
all�� bacteria t� bin� t� e�ithelia 
�f infecte� h�sts,� like E. coli ��es 
in urinary tract infecti�ns. Pili are 
self-assemblin� chains �f �r�tein 
subunits,� an� the mechanisms �f their  
assembly have been eluci�ate� in 
s�me �etail in recent years (Remaut 
et al. (2008),� Cell 133,� 640–652). The 
research �r�u� �f Fre�rik Almqvist 
at the University �f Umeå,� S�e�en,� 
has alrea�y synthesise� an� starte� 
testin� a number �f synthetic 
chemicals �evel��e� �ith the aim �f 
interferin� �ith the assembly �f �ili. 
A recent structure-activity survey 
fr�m the �r�u� has in�ee� reveale� 
s�me �r�misin� �ru� can�i�ates 
(E. Ch�rell et al. (2012),� Bi��r�. Me�. 
Chem. htt�://�x.��i.�r�/10.1016/
j.bmc.2012.01.048). 
Researchers are als� tar�etin� 
the secreti�n systems that enable 
�ath��enic bacteria t� exu�e their 
t�xins,� �hich are �ften the main 
cause �f the harm that the �ath��ens ��. The �r�u� �f Richar� Pickers�ill 
at Queen Mary,� University �f L�n��n,� 
has recently re��rte� �r��ress in the 
structural an� functi�nal stu�ies �f 
the ty�e II secreti�n system,� �hich 
is active in Vibrio cholerae as �ell 
as in �ath��enic strains �f E. coli 
(PL�S Path��. (2012) 8,� e1002531. 
��i:10.1371/j�urnal.��at.1002531).
An�ther alternative that has 
ex�erience� a renaissance �f s�rts 
in recent years is the thera�eutic use 
�f bacteri��ha�es (Curr. Bi�l. (2011),� 
21,� R267–R270). One si�nificant 
issue there is �hether the use �f 
mixtures �f �ha�es,� kn��n as �ha�e 
c�cktails,� is m�re efficient than that 
�f s�ecific sin�le s�ecies �f �ha�es. 
“The ��tential ��rry in terms �f 
usin� �ha�e c�cktails is that they 
select f�r bacteria that are n�t �nly 
m�re resistant t� the �ha�es use� in 
the treatment,� but als� ne� �ha�es 
that they have n�t ex�erience�. In 
�ther ��r�s,� the c�cktail treatment 
mi�ht,� in fact,� select f�r a �eneral 
resistance mechanism,� makin� 
future treatment less effective,�” 
ex�lains Britt K�skella fr�m the 
University �f Exeter,� UK. “We teste� 
this i�ea usin� �ha�es that infect 
the �lant �ath��en,� Pseudomonas 
syringae �f t�mat�,� an� f�un� that 
usin� a c�cktail �i� n�t hin�er 
the ev�luti�n �f resistance. The 
���� ne�s is that,� at least f�r the 
�ha�e c�mbinati�ns �e use�,� the 
c�cktail �i� n�t select f�r increase� 
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Infectious agent: C�l�ure� transmissi�n electr�n micr��ra�h (TEM) �f a sin�le Beijin� influenza 
virus. The virus c�nsists �f a c�re �f RNA (re�) surr�un�e� by a s�ike� �r�tein envel��e �f 
haema��lutinin (br��n). The s�ikes a�here t� h�st cells �urin� infecti�n. (Ph�t�: Science 
Ph�t� Library.)resistance a�ainst future �ha�es,�” 
K�skella says. S� c�mbinin� �ha�es 
in a c�cktail treatment seems t� �� 
neither harm n�r ���� (Pr�c. R. S�c. 
B (2011),� ��i:10.1098/rs�b.2011.2259). 
H��ever,� her research als� f�un� 
that the c�st �f a�a�tin� t� multi�le 
�ha�es re�uces the fitness �f the 
survivin� bacterial strains,� c�m�are� 
�ith th�se that �nly ha� t� c��e �ith 
a sin�le �ha�e s�ecies. 
Researchers have als� h��e� that 
antimicr�bial �e�ti�es �f the ty�e 
that �as first �isc�vere� in fr�� skin 
in the 1980s mi�ht be �evel��e� 
int� antimicr�bial �ru�s t� ste� in 
f�r tra�iti�nal antibi�tics. A recent 
fin�in� fr�m the �r�u� �f Michael 
Br�ckhurst at the University �f 
Liver���l,� h��ever,� may �eflate this 
h��e. The researchers f�un� that 
Staphylococcus aureus n�t �nly 
mana�e� t� �evel�� resistance t� the 
�e�ti�e �exi�anan,� a �ru� can�i�ate 
f�r �iabetic le�-ulcer infecti�ns,� but,� 
m�re ��rryin�ly,� in s�me instances als� �evel��e� cr�ss-resistance 
t� �efensin-1 �f human neutr��hils 
after bein� ex��se� t� the �e�ti�e. 
The results,� the researchers �rite 
“hi�hli�ht a �rave ��tential risk �f 
AMP thera�ies”.
Viral threats
Mean�hile,� humanity is als� 
vulnerable t� infecti�us �iseases 
that antibi�tics can’t �� anythin� 
ab�ut,� namely th�se �ri�inatin� 
fr�m viruses. Recent �utbreaks �f 
flu variants �ri�inatin� in animals 
inclu�in� bir�s an� s�ine have 
hei�htene� �ur a�areness �f the 
threat ��se� by viral z��n�ses,� 
i.e. �iseases that jum� the s�ecies 
barrier an� bec�me transmissible 
bet�een humans. This threat has 
been �ith us since the inventi�n 
�f a�riculture,� an� t��ay’s mil� 
chil�h��� infecti�ns are the embers 
�f much m�re virulent �iseases that 
are als� believe� t� have c�me fr�m 
animals an� t� have �eakene� �ver centuries �f c�-ev�luti�n �ith their 
ne� human h�sts. H��ever,� t��ay’s 
�l�bal travel habits increase the 
�an�er by makin� it ��ssible f�r a 
ne� �an�emic t� s�rea� ar�un� the 
�l�be in a sh�rt time. 
A �articular cause f�r c�ncern lies 
in the avian flu strains carryin� the 
H5 haema��lutinin,� such as H5N1. 
This strain is �i�es�rea� am�n� 
bir�s in S�utheast Asia. Fr�m 2003 
t� the en� �f 2011,� there �ere 578 
c�nfirme� cases �f humans infecte� 
�ith this strain,� an� m�re than half 
(340) �f th�se infecte� �ie�. S� far,� 
all victims �f this strain have been 
infecte� by c�ntact �ith bir�s,� s� the 
virus seems t� be unable t� s�rea� 
fr�m �ne human t� an�ther,� e.�. via 
aer�s�ls. The ��rry is that if an H5 
virus sh�ul� s�meh�� acquire the 
ability t� s�rea� bet�een humans,� 
the resultin� �an�emic c�ul� kill 
many milli�ns �f �e��le. 
As the virus hasn’t acquire� 
this ability yet,� s�me ex�erts 
��timistically assume� it mi�ht be 
intrinsically unable t� �� s�. H��ever,� 
t�� research �r�u�s have n�� 
in�e�en�ently an� �n �ifferent �aths 
arrive� at a variant H5 virus that is 
easily transmissible bet�een ferrets,� 
the mammalian m��el system �f 
ch�ice f�r such stu�ies. This fin�in� 
b�th un�ermine� �ur sense �f security 
that the H5 �an�emic mi�ht never 
ha��en an� a��e� a ne� viral threat 
t� �ur c�llective fears,� namely that 
human-transmissible H5 viruses 
c�ul� be en�ineere� an� use� as 
bi��ea��ns. 
The relevant �ublicati�ns by 
Y�shihir� Ka�a�ka’s �r�u� at the 
University �f Wisc�nsin in Ma�is�n 
an� by R�n F�uchier’s team at 
the Erasmus Me�ical Center in 
R�tter�am,� Netherlan�s,� have been 
acce�te� by Nature an� Science,� 
res�ectively,� but b�th j�urnals 
refraine� fr�m �ublishin� the full 
scientific �etails f�r fear they mi�ht 
�r�vi�e a blue�rint f�r bi��ea��ns. 
The j�urnals share� the results �ith 
the US Nati�nal Science A�vis�ry 
B�ar� f�r Bi�security (NSABB),� 
�hich rec�mmen�e� �ublicati�n 
�f the �a�ers in a re�acte� f�rm 
�ith�ut full �etails. 
In a �etaile� statement �ublishe� 
b�th in Nature an� in Science,� 
the NSABB ackn��le��e� the 
im��rtance �f the ��rk,� �hich f�r 
the first time �em�nstrate� that 
H5 viruses can easily bec�me 
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�atches �f my family t� un�erstan� 
h�� they ��rke�. I exten�e� this 
t� m�t�rbike en�ines an� seri�usly 
c�nsi�ere� �ursuin� a career as a 
bu��in� racin� en�ineer. Over the 
summer �ri�r t� enterin� university,� I 
rea� a b��k �n clinical �sych�l��y an� 
realize� the t�rments �f the brain �ere 
n�t entirely unlike th�se in the ��n�. 
This �eci�e� me t� stu�y �sych�l��y.
It �as �hen I rea� D�u�las 
H�fsta�er’s G��el,� Escher,� Bach that 
everythin� came t��ether. At the time,� 
I �as a juni�r research assistant in 
�sych�l��y in Lie�e (Bel�ium). What 
fascinate� me �as h�� a��arently 
serial th�u�hts c�ul� emer�e fr�m 
many l��er-level neur�nal 
mechanisms — �e have s� many 
neur�ns,� �hy �� �e have s� very 
fe� th�u�hts? Virtual machines in 
c�m�uter science �ffere� a meta�h�r 
f�r this ‘re�ucti�n’ bet�een c��niti�n 
an� the brain,� the c�nnecti�nist 
frame��rk s�me m��ellin� t��ls an� 
�hil�s��hy s�me f��� f�r th�u�ht �n 
the f�rms that this re�ucti�n c�ul� 
take. This c�nvince� me 
t� stu�y c�m�uter science in Bel�ium,� 
�ith �reat interest in aut�mata the�ry 
an� the c�nstraints it ��ses �n �hat 
is c�m�utable an� theref�re can be 
m��elle� an� ultimately un�erst��� as 
a mechanism. 
Ultimately,� I left f�r the US. It �as 
then the �nly c�untry �here I c�ul� 
�ursue my inter�isci�linary interests. 
My PhD in C��nitive Science at Br��n 
University �ffere� a truly re�ar�in� 
intellectual ex�erience an� ha� a bi� 
im�act �n me — �ith lectures fr�m 
Dan Kersten (c�m�utati�nal visi�n),� 
Jim An�ers�n (neural net��rk m��els),� 
Gre��ry Mur�hy (c�nce�t learnin� 
an� cate��rizati�n),� Jae���n Kim 
(�hil�s��hy �f min�),� Ulf Grenan�er 
an� Stuart Geman (statistical �attern 
rec��niti�n). Br��n �as my first 
ex�erience �f a rich envir�nment �ith a 
free fl�� �f th�u�hts bet�een A��lie� 
Mathematics,� Neur�science,� C��nitive 
Science an� Phil�s��hy. I relishe� 
these years an� have since then striven 
t� �evel�� a similar research culture.
L��kin� back,� I �as f�rtunate t� 
ex�erience the benefits �f the US 
e�ucati�nal system in my f�rmative 
years. It �as then �ell ahea� �f Eur��e 
in the ����rtunities that it �ffere� (an� 
still �ffers) f�r �enuine inter�isci�linary 
trainin�. An� �ne c�ul� easily ar�ue 
that Eur��e still has s�me �r�un�s t� 
c�ver t� bri��e bet�een �isci�lines in 
un�er�ra�uate an� �ra�uate teachin�. 
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What turned you on to science in 
general, and to visual neuroscience 
in particular, in the first place? It 
ha��ene� in �rimary sch��l,� �n 
a Fri�ay aftern��n,� an� it �as an 
e�i�hany. We ha� a Fri�ay h�ur �urin� 
�hich �ur teacher ��ul� entertain 
us �ith st�ries,� t� kee� �ur attenti�n 
levels hi�h an� �ur misbehavin� l��. 
On this �articular �ay,� he starte� t� 
�escribe a small quiet ��n� as a casual 
�bserver ��ul� ex�erience it,� as a 
still s�rea� �f �ater �ith a fe� �ater 
lilies an� a variety �f insects s�armin� 
near the surface. With�ut transiti�n,� he 
s�itche� fr�m this �ast�ral �escri�ti�n 
t� a brutal ren�erin� �f the rich life 
an� the fi�ht f�r survival ha��enin� 
beneath still �aters. As time �as 
tickin�,� he st���e� the st�ry an� left it 
unfinishe�. He �r�mise� t� resume the 
�escri�ti�n �f nature’s battlefiel� the 
f�ll��in� Fri�ay,� but it never ha��ene�. 
I �aite� ex�ectantly f�r the st�ry t� 
finish,� literally every sin�le Fri�ay �f the 
year,� but it never �i�. 
In my turbulent hi�h-sch��l years,� I 
�as very f�rtunate that a �atient an� 
un�erstan�in� bi�l��y teacher �ave 
me a textb��k �n the bi�l��y �f the cell 
t� rea� an� re��rt �n. This �enerate� 
a �enuine fascinati�n f�r �etaile� an� 
c�m�lex mechanisms. Cl�ck��rks als� 
intereste� me an� I s�ent c�nsi�erable 
time �ismantlin� the 19th century 
Q & Atransmissible bet�een mammals. H��ever,� the NSABB als� states 
that “these scientific results als� 
re�resent a �rave c�ncern f�r �l�bal 
bi�security,� bi�safety an� �ublic 
health”. The analysis c�nclu�es that 
“because the NSABB f�un� that 
there �as si�nificant ��tential 
f�r harm in fully �ublishin� these 
results an� that the harm excee�e� 
the benefits �f the �ublicati�n,� �e 
theref�re rec�mmen�e� that the 
��rk n�t be fully c�mmunicate� in 
an ��en f�rum”. 
B�th �r�u� lea�ers have �r�teste� 
a�ainst the �ecisi�n,� claimin� that 
full �ublicati�n �f their results ��ul� 
n�t create a��iti�nal risks. Ka�a�ka 
�rites in a c�mmentary in Nature: 
“I believe that the benefits �f these 
stu�ies — the kn��le��e that H5 
HA-��ssessin� viruses ��se a risk 
an� the ability t� m�nit�r them 
an� �evel�� c�untermeasures — 
�ut�ei�h the risk.” 
Other ex�erts are n�t s� sure 
that there is an imme�iate benefit 
t� be �aine� fr�m �i�es�rea� 
sharin� �f the �etails,� as there is n� 
infrastructure in �lace that ��ul� 
enable anyb��y t� m�nit�r f�r the 
emer�ence �f human transmissible 
H5 viruses in nature. “Surveillance 
�f influenza in animals is sl�� an� 
�atchy at best,� an� the f�ll��-u� 
sequencin� �f sam�les m�re s�,�” 
bem�ans an e�it�rial in Nature. 
Even if a �an�er�us H5 virus �ith 
mutati�ns similar t� the �nes 
create� in the lab �as �icke� u� 
by m�nit�rin� eff�rts early �n,� it is 
n�t clear that this ��ul� im�r�ve 
�ur chances. “At �resent,� such 
a�vance kn��le��e ��ul� make 
little �ifference t� the ��rl�’s 
limite� abilities t� manufacture an� 
�istribute vaccines,�” the e�it�rial 
c�nclu�es. 
Given the hi�hly c�ntr�versial 
�ebate �n these �r�blems,� flu 
researchers have a�ree� a 60-�ay 
m�rat�rium �n this kin� �f research,� 
t� all�� scientists an� ��liticians 
time t� fin� safe �ays �f han�lin� 
such �an�er�us inf�rmati�n. They 
may als� �ant t� im�r�ve their 
c�ntin�ency �lans f�r the case that 
a human-transmissible H5 virus,� be 
it fr�m nature �r fr�m the lab,� ��es 
start a �an�emic. 
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